Lanasa, M.

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Drew, Y., de Jonge, M., Hong, S. H., Park, Y. H., Wolfer, A., Brown, J., Ferguson, M., Gore, M. E., Alvarez, R. H., Gresty, C., et al. (2018) · Gynecologic Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 131

Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia

Lanasa, M. C., Davis, P. H., Datto, M., Li, Z., Gockerman, J. P., Moore, J. O., DeCastro, C. M., Friedman, D. R., Diehl, L. F., Rehder, C., et al. (2012) · Leukemia & Lymphoma

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 16